Newer antifungal therapy for emerging fungal pathogens

International Journal of Infectious Diseases

Volumn 7, Issue 1, 2003, Pages 5-20

  Steinbach, William J ^a,b   Perfect, John R ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; AZITHROMYCIN; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TERBINAFINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG POTENTIATION; DRUG SENSITIVITY; EPIDEMIOLOGICAL DATA; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; FUSARIUM; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPETENCE; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MYCOSIS; NONHUMAN; PAECILOMYCES; PENICILLIUM; PHAEOHYPHOMYCOSIS; REVIEW; RHODOTORULA; SCEDOSPORIUM; SPECIES DIFFERENCE; TOXICITY; TRICHODERMA; TRICHOSPORON;

EID: 0037346091     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(03)90037-3     Document Type: Review

References (134)

1. Groll AH, Shah PM, Mentzel C, et al. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
2. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect Dis 1999; 1:247-261.
3. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9:499-511.
4. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22(suppl 2):S112-S118.
5. Richter S, Cormican MG, Pfaller MA, et al. Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. J Clin Microbiol 1999; 37:1154-1160.
6. Ponton J, Ruchel R, Clemons KV, et al. Emerging pathogens. Med Mycol 2000; 38(suppl 1):225-236.
7. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(suppl 2):S89-S94.
8. Liebowitz LD, Ashbee HR, Evans EGV, et al. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis 2001; 4:27-33.
9. Krcmery V. Torulopsis glabrata an emerging yeast pathogen in cancer patients. Int J Antimicrob Agents 1999; 11:1-6.
10. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8:462-478.
11. Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in non-albicans Candida species. Drug Resist Updates 1999; 2:9-14.
12. Sullivan DJ, Westerneng TJ, Haynes KA, et al. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995; 141:1507-1521.
13. Pfaller MA, Messer SA, Gee S, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999; 37:870-872.
14. Borg-von Zepelin M, Niederhaus T, Tintelnot K. Adherence of clinical Candida dubliniensis isolates in the presence of fluconazole [Abstract 38]. In: 14th Congress of the International Society for Human and Animal Mycology, 2000. Buenos Aires: ISHAM, 2000.
15. Curfs JHAJ, Ruhnke M, Kullberg BJ, et al. Difference in virulence of Candida dubliniensis strains in mice and comparison to C. albicans [Abstract 528]. In: 14th Congress of the International Society for Human and Animal Mycology, 2000. Buenos Aires: ISHAM, 2000.
16. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950-2956.
17. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41:2333-2338.
18. Graybill JR, Bocanegra R, Luther M, et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 1997; 41:1937-1939.
19. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole + placebo vs. fluconazole + amphotericin B as treatment of candidemia in non-neutropenic patients [Abstract J-681a]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001.
20. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-1330.
21. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029.
22. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000; 30:14-18.
23. Yoon SA, Vazquez JA, Steffan PE, et al. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 1999; 43:836-845.
24. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-678.
25. Pietrucha-Dilanchian P, Lewis RE, Ahmad H, et al. Candida lusitaniae catheter-related sepsis. Ann Pharmacother 2001; 35:1570-1574.
26. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994; 7:479-504.
27. Cho CT, Vats TS, Lowman JT, et al. Fusarium solani infection during treatment for acute leukemia. J Pediatr 1973; 83:1028-1031.
28. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999-1008.
29. Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33:1871-1878.
30. Schell WA. New aspects of emerging fungal pathogens: a multifaceted challenge. Clin Lab Med 1995; 15:365-387.
31. Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy studies with caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46:245-247.
32. Clancy C, Nguyen MH. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother 1998; 41:127-130.
33. Guarro J, Pujol I, Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother 1999; 43:1256-1257.
34. Anaissie EJ, Hachem R, Legrand C, et al. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis 1992; 165:1155-1157.
35. Lozano-Chiu M,Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999; 43:589-591.
36. Reyes GH, Long L, Hossain M, et al. Evaluation of voriconazole efficacy in the treatment of murine fusariosis [Abstract J-1604]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001.
37. Ortoneda M, Pastor FJ, Pujol C, et al. Successful treatment of murine fusariosis with high doses of liposomal amphotericin B [Abstract J-1830]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001.
38. Musa MO, AI Eisa A, Halim M, et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immuno-compromised patients: a single institution experience over 10 years. Br J Haematol 2000; 108:544-548.
39. Pujol I, Guarro J, Gene J, et al. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39:163-167.
40. Hennequin C, Lavarde V, Poirot J, et al. Invasive Fitsarium infections: a retrospective survey of 31 cases. The French Groupe d'Etudes des Mycoses Opportunistes' GEMO. J Med Vet Mycol 1997; 35:107-114.
41. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-1396.
42. Cofrancesco E, Boschetti C, Viviani MA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the eradication of Fusarium infection in a leukemic patient. Haematologica 1992; 77:280-283.
43. Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84:932-933.
44. Menon A, Siraj D, Ruhe J, et al. Fusarium peritonitis successfully treated with voriconazole [Abstract 20]. In: Focus on fungal infections 12, Phoenix, AZ. Atlanta, GA: Imedex, 2002.
45. Perfect JR, Lutsar I, Gonzalez-Ruiz A. Voriconazole for the treatment of resistant and rare fungal pathogens [Abstract 303]. In: 38th Infectious Diseases Society of America Meeting, New Orleans, LA. Alexandria, VA: IDSA, 2000.
46. Hachem RY, Raad II, Afif CM, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH56592) in the treatment of invasive fungal infections refractory to or intolerant to standard therapy [Abstract 1109]. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario. Washington, DC: American Society for Microbiology, 2000.
47. Munoz P, Marin M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:499-501.
48. Meletiadis J, Meis JFGM, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46:62-68.
49. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45:2151-2153.
50. Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore) 1997; 76:256-265.
51. Meletiadis J, Meis JFGM, Mouton JW, et al. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38:2949-2954.
52. Meletiadis J, Mouton JW, Meis JFGM, et al. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect 2000; 6:336-337.
53. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000; 44:470-472.
54. Meletiades J, Mouton JW, Meis JFG, et al. Comparison of different models to determine the in vitro synergistic interaction between voriconazole and terbinafine against Scedosporium prolificans [Abstract J-126]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001.
55. Walsh TJ, Peter J, McGough DA, et al. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995; 39:1361-1364.
56. Afeltra J, Dannaoui E, Mouton JW, et al. Synergistic effect of amphotericin B and pentamidine against clinical isolates of Scedosporium prolificans [Abstract J-121]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001.
57. Gonzalez G, Tijerina R, Najvar L, et al. Therapeutic efficacy of posaconazole in a murine Pseudallescheria boydii infection [Abstract J-1615]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001.
58. Gosbell IB, Morris ML, Gallo JH, et al. Clinical pathologic and epidemiologic features of infection with Scedosporium prolificans: four cases and review. Clin Microbiol Infect 1999; 5:672-686.
59. Cimon B, Carrere J, Vinatier JF, et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19:53-56.
60. Beguin H, Nolard N. Mould biodiversity in homes. Air and surface analysis of 130 dwellings. Aerobiologia 1994; 10:157-166.
61. Verweij PE, Cox NJ, Meis JFGM. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur J Clin Microbiol Infect Dis 1997; 16:26-28.
62. Girmenia C, Luzi G, Monaco M, et al. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998; 36:1436-1438.
63. Jabado N, Casanova J-L, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998; 27:1437-1441.
64. Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000; 31:673-676.
65. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, et al. Voriconazole for the treatment of S. apiospermum and S. prolificans infection [Abstract 305]. In: 38th Infectious Diseases Society of America Meeting, New Orleans, LA, 2000.
66. Revankar SG, Patterson JE, Sutton DA, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34:467-476.
67. Cano J, Guarro J, Mayayo E, et al. Experimental infection with Scedosporium inflatum. J Med Vet Mycol 1992;30:413-420.
68. Imwidthaya P, Thipsuvan K, Chaiprasert A, et al. Penicillium marneffei: types and drug susceptibility. Mycopathologia 2000; 149:109-115.
69. DiSalvo AF, Fickling AM, Ajello L. Infection caused by Penicillium marneffei: description of first natural infection in man. Am J Clin Pathol 1973; 60:259-263.
70. Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23:125-130.
71. Sirisanthana T, Supparatpinyo K, Perriens J, et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffi infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:1107-1110.
72. McGinnis MR, Nordoff NG, Ryder NS, et al. In vitro comparison of terbinafine and itraconazole against Penicillium marneffei. Antimicrob Agents Chemother 2000; 44:1407-1408.
73. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997; 41:841-843.
74. Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents 2001; 18:167-172.
75. Uchida K, Nishiyama Y, Yokota N, et al. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiotics 2000; 53:1175-1181.
76. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999; 43:1401-1405.
77. Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thailand 1992; 75:688-691.
78. Guarro J, Gams W, Pujol I, et al. Acremonium species: new emerging fungal opportunists - in vitro antifungal susceptibilities and review. Clin Infect Dis 1997; 25:1222-1229.
79. McGinnis MR, Pasarell L, Sutton DA, et al. In vitro activity of voriconazole against selected fungi. Med Mycol 1998; 36:239-242.
80. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillits spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002; 46:1032-1037.
81. Fincher R-ME, Fisher JF, Lovell RD, et al. Infection due to the fungus Acremonium (Cephalosporium). Medicine (Baltimore) 1991; 70:398-409.
82. Dixon DM, Walsh TJ, Merz WG, et al. Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis 1989; 11:515-525.
83. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dermatiaceous fungi. J Clin Microbiol 2001; 39:954-958.
84. McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol 1998; 36:243-246.
85. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42:741-745.
86. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36:198-202.
87. Del Poeta M, Schell WA, Perfect JR. In vitro activity of pneumocandin L-743-872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41:1835-1836.
88. Kremery VJ, Mateicka F, Kunova A, et al. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazole. Support Care Cancer 1999; 7:39-43.
89. Moretti-Branchini ML, Fukushima K, Schreiber AZ, et al. Trichosporon species infection in bone marrow transplanted recipients. Diagn Microbiol Infect Dis 2001; 39:161-164.
90. Paphitou NI, Ostrosky-Zeichner L, Paetznick V, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144-1146.
91. Uzun O, Arikan S, Kocagoz S, et al. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish university hospital and effect of time of reading. Diagn Microbiol Infect Dis 2000; 38:101-107.
92. Carrillo-Munoz AJ, Quindos G, Tur C, et al. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999; 44:397-401.
93. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57-62.
94. Uzun O, Kocagoz S, Cetinkaya Y, et al. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997; 41:1156-1157.
95. Wolf DG, Falk R, Hacham M, et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol 2001; 39:4420-4425.
96. Kataoka-Nishimura S, Akiyama H, Saku K, et al. Invasive infection due to Trichosporon cutaneum in patients with hematologic malignancies. Cancer 1998; 82:484-487.
97. Chaumentin G, Boibieux A, Piens MA, et al. Trichosporon inkin endocarditis: short-term evolution and clinical report. Clin Infect Dis 1996; 23:396-397.
98. Lopes JO, Alves SH, Klock C, et al. Trichosporon inkin peritonitis during continuous ambulatory peritoneal dialysis with bibliography review. Mycopathologia 1997; 139:15-18.
99. Anaissie E, Bodey G. Disseminated trichosporonosis: meeting the challenge. Eur J Clin Microbiol Infect Dis 1991; 10:711-713.
100. Shimazu K, Ando M, Sakata T, et al. Hypersensitivity pneumonitis induced by Trichosporon cutaneum. Am Rev Respir Dis 1984; 130:407-411.
101. Anaissie E, Gokaslan A, Hachem R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992; 15:781-787.
102. Anaissie EJ, Hachem R, Karyotakis NC, et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother 1994; 38:2541-2544.
103. Goodman D, Pamer E, Jakubowski A, et al. Breakthrough trichosporonosis in a bone marrow transplant patient receiving caspofungin acetate. Clin Infect Dis 2002; 35:35-36.
104. Samonis G, Anatoliotaki M, Apostolakou H, et al. Transient fungemia due to Rhodotorula rubra in a cancer patient: case report and review of the literature. Infection 2001; 29:173-176.
105. Kiehn TE, Gorey E, Brown AE, et al. Sepsis due to Rhodotorula related use of indwelling central venous catheters. Clin Infect Dis 1992; 14:841-846.
106. Galan-Sanchez F, Garcia-Martos P, Rodriguez-Ramos C, et al. Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples. Mycopathologia 1999; 145:109-112.
107. Barchiesi F, Arzeni D, Fothergill AW, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000; 44:226-229.
108. Alliot C, Desablens B, Garidi R, et al. Opportunistic infection with Rhodotorula in cancer patients treated with chemotherapy: two case reports. Clin Oncol 2000; 12:115-117.
109. Furukawa H, Kusne S, Sutton DA, et al. Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient. Clin Infect Dis 1998; 26:487-489.
110. Munoz FM, Demmler GJ, Travis WR, et al. Trichoderma longibrachiatum infection in a pediatric patient with aplastic anemia. J Clin Microbiol 1997; 35:499-503.
111. Sequin P, Degeilh B, Grulois I, et al. Successful treatment of a brain abscess due to Trichoderma longibrachiatum after surgical resection. Eur J Clin Microbiol Infect Dis 1995; 14:445-448.
112. Tanis BC, van der Pijl H, van Ogtrop ML, et al. Fatal fungal peritonitis by Trichoderma longibrachiatum complicating peritoneal dialysis. Nephrol Dialysis Transplant 1995; 10:114-116.
113. Espinel-Ingroff A. Comparison of the E-test with NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001; 39:1360-1367.
114. Saberhagen C, Klotz SA, Bartholomew W, et al. Infection due to Paecilomyces lilacinus: a challenging clinical identification. Clin Infect Dis 1997; 25:1411-1413.
115. Tan TQ, Ogden AK, Tillman J, et al. Paecilomyces lilacinus catheter-related fungemia in an immunocompromised pediatric patient. J Clin Microbiol 1992; 30:2479-2483.
116. Liu K, Howell DN, Perfect JR, et al. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces and Acremonium species by histopathology. Am J Clin Pathol 1998; 109:45-54.
117. Sugar AM. Mucormycosis. Clin Infect Dis 1992; 14(suppl 1):S126-S129.
118. Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851-856.
119. Espinel-Ingroff A, Oakley LA, Kerkering TM. Opportunistic zygomycotic infections. Mycopathologica 1987; 97:33-41.
120. Otcenasek M, Buchta V. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens. Mycopathologica 1994; 128:135-137.
121. Wilfeuer A, Seidl HP, Paule I, et al. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998; 41:309-319.
122. Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002; 46:1581-1582.
123. Boelaert JR. Mucormycosis (ZM): is there news for the clinician? J Infect 1994; 28(suppl 1):1-6.
124. Ingram CW, Sennesh J, Cooper JN, et al. Disseminated zygomycosis: report of four cases and review. Rev Infect Dis 1989; 11:741-754.
125. Leleu X, Sendid B, Fruit J, et al. Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24:417-420.
126. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-1396.
127. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: a clinicopathologic study of 33 cases. Medicine (Baltimore) 1986; 65:113-123.
128. National Committee for Clinical and Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi. Proposed standard M38-P. Wayne, PA: NCCLS, 1998.
129. Krishnarao TV, Galgiani JN. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41:1957-1960.
130. Vasquez JA, Lynch M, Boikov D, et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41:1612-1614.
131. Clancy C, Nguyen N. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17:573-575.
132. Huczko E, Minassian B, Washo T, et al. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates [Abstract J-810]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001.
133. Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37:3946-3951.
134. Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, et al. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999; 43:149-151.